HK1209766A1 - Exendin-4 derivatives as dual glp1/glucagon agonists - Google Patents

Exendin-4 derivatives as dual glp1/glucagon agonists

Info

Publication number: HK1209766A1
Authority: HK; Hong Kong
Prior art keywords: carboxy; butyryl; lys; ethoxy; amino acid
Prior art date: 2012-10-09

Application number

HK15110559.5A

Other languages

German (de)

English (en)

French (fr)

Chinese (zh)

Other versions

HK1209766B (en

Inventor

Torsten Haack

Michael Wagner

Bernd Henkel

Siegfried Stengelin

Andreas Evers

Martin Bossart

Original Assignee

Sanofi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-09

Filing date

2013-10-08

Publication date

2016-04-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1209766(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-10-08 Application filed by Sanofi filed Critical Sanofi

2016-04-08 Publication of HK1209766A1 publication Critical patent/HK1209766A1/en

2018-06-29 Publication of HK1209766B publication Critical patent/HK1209766B/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Obesity (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Addiction (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)

HK15110559.5A 2012-10-09 2013-10-08 Exendin-4 derivatives as dual glp1/glucagon agonists HK1209766B (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP12306232.5		2012-10-09
EP12306232		2012-10-09
EP13305222		2013-02-27
EP13305222.5		2013-02-27
PCT/EP2013/070882 WO2014056872A1 (en)	2012-10-09	2013-10-08	Exendin-4 derivatives as dual glp1/glucagon agonists

Publications (2)

Publication Number	Publication Date
HK1209766A1 true HK1209766A1 (en)	2016-04-08
HK1209766B HK1209766B (en)	2018-06-29

Family

ID=

Also Published As

Publication number	Publication date
HUE037150T2 (hu)	2018-08-28
US20180185450A1 (en)	2018-07-05
LT2906595T (lt)	2017-11-27
JP2015532297A (ja)	2015-11-09
UY35072A (es)	2014-05-30
TW201427992A (zh)	2014-07-16
US20140100156A1 (en)	2014-04-10
MY168749A (en)	2018-11-30
DOP2015000073A (es)	2015-05-31
UA116217C2 (uk)	2018-02-26
AU2013328802A1 (en)	2015-05-07
US20160220643A1 (en)	2016-08-04
HRP20171726T1 (hr)	2017-12-29
KR102179751B1 (ko)	2020-11-17
CN104837864B (zh)	2019-07-05
EA030023B1 (ru)	2018-06-29
IL237641B (en)	2019-06-30
CN104837864A (zh)	2015-08-12
PT2906595T (pt)	2017-11-16
RS56515B1 (sr)	2018-02-28
TN2015000101A1 (en)	2016-06-29
WO2014056872A1 (en)	2014-04-17
MX359533B (es)	2018-10-01
CL2016002137A1 (es)	2017-12-22
DK2906595T3 (da)	2017-11-27
AR092925A1 (es)	2015-05-06
CY1119987T1 (el)	2018-12-12
TWI613213B (zh)	2018-02-01
CR20150200A (es)	2015-06-11
PH12015500688A1 (en)	2015-05-25
JP6373270B2 (ja)	2018-08-15
ZA201501694B (en)	2016-01-27
PE20150900A1 (es)	2015-06-16
NO2906595T3 (da)	2018-01-13
AU2013328802B2 (en)	2017-10-12
SI2906595T1 (sl)	2017-12-29
BR112015007685A2 (pt)	2017-08-08
CL2015000811A1 (es)	2015-09-11
EP2906595A1 (en)	2015-08-19
KR20150064093A (ko)	2015-06-10
NZ706898A (en)	2018-02-23
CA2887272A1 (en)	2014-04-17
CA2887272C (en)	2021-09-21
EA201590715A1 (ru)	2015-11-30
ES2647418T3 (es)	2017-12-21
IL237641A0 (en)	2015-04-30
US9365632B2 (en)	2016-06-14
MX2015004531A (es)	2015-12-01
GT201500081A (es)	2017-12-15
US10758592B2 (en)	2020-09-01
PH12015500688B1 (en)	2015-05-25
SG11201501770WA (en)	2015-04-29
EP2906595B1 (en)	2017-08-16
PL2906595T3 (pl)	2018-01-31

Publication	Publication Date	Title
US10758592B2 (en)	2020-09-01	Exendin-4 derivatives as dual GLP1/glucagon agonists
US10253079B2 (en)	2019-04-09	Functionalized Exendin-4 derivatives
EP3129395B1 (en)	2018-12-19	Exendin-4 derivatives as peptidic dual glp-1 / glucagon receptor agonists
EP3129397B1 (en)	2019-01-09	Peptidic dual glp-1 / glucagon receptor agonists derived from exendin-4
AU2015243611B2 (en)	2018-11-08	Dual GLP-1 / glucagon receptor agonists derived from exendin-4
HK1209766B (en)	2018-06-29	Exendin-4 derivatives as dual glp1/glucagon agonists
HK1262784A1 (en)	2020-01-17	Functionalized exendin-4 derivatives
HK1211233B (en)	2019-06-21	Exendin-4 derivatives as dual glp1/gip- or trigonal glp1/gip/glucagon agonists

Legal Events

Date	Code	Title	Description
2023-05-05	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20221011